Compare Nasdaq100 ETF (QQQ) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nasdaq100 ETF vs Travere Therapeutics Inc. Common Stock — how do they compare? Nasdaq100 ETF trades at $720.1 (market cap $506.12B), while Travere Therapeutics Inc. Common Stock trades at $53.44 (market cap $5.02B). The key difference: Nasdaq100 ETF is far larger — about 100.8× Travere Therapeutics Inc. Common Stock's market cap, and Nasdaq100 ETF is trading nearer its 52-week high, Travere Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Nasdaq100 ETF for 163 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| QQQ | TVTX | |
|---|---|---|
Market Cap | $506.12B | $5.02B |
Volume | 51,534,028 | 2,060,842 |
52-Week High | $759.66 | $67.52 |
52-Week Low | $558.34 | $26.79 |
Typical Hold Time | 163 Days | 0 Days |
Sector | — | Health |
Enterprise Value | — | $5.15B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QQQ trades at $743.57, down 0.32% on the day, with a bullish technical signal from moving averages despite neutral oscillators. The ETF shows mixed analyst sentiment with a 50% buy and 50% sell consensus. Recent news highlights QQQ's strong decade-long performance and ongoing innovation with new international ETF launches, though concerns about AI market valuations and expense ratios compared to competitors like QQQM persist.
Outlook remains cautiously optimistic given QQQ's tech-heavy exposure and AI-driven growth potential, but risks include market volatility from Fed rate hikes, high concentration in tech stocks, and valuation concerns. The dividend of $0.75 payable in October 2026 provides minor income support.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Nasdaq100 ETF
The ETF is designed to track the performance of the securities and the stocks in the NASDAQ-100 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on QQQ →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
